Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melflufen plus dexamethasone in relapsed or relapsed-refractory multiple myeloma
NL-OMON47533Phase 1Active, not recruiting
- Sponsor
- Oncopeptides AB
- Start
- Sep 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of melphalan flufenamide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Oncopeptides AB. Primary endpoints: Maximum tolerated dose and Objective response rate and clinical benefit. Started Sep 2013; status: active, not recruiting.
02
Drugs
melphalan flufenamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON47533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47533.